Net Cash Provided by (Used in) Financing Activities of TENAX THERAPEUTICS, INC. from 31 Jul 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
TENAX THERAPEUTICS, INC. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Jul 2010 to 31 Dec 2025.
  • TENAX THERAPEUTICS, INC. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $23,563,000, a 197% increase year-over-year.
  • TENAX THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $38,514,000, a 61% decline from 2024.
  • TENAX THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $99,870,000, a 636% increase from 2023.
  • TENAX THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $13,569,000, a 71% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

TENAX THERAPEUTICS, INC. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $38,514,000 -$61,356,000 -61% 01 Jan 2025 31 Dec 2025 10-K 10 Mar 2026 2025 FY
2024 $99,870,000 +$86,301,000 +636% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2026 2025 FY
2023 $13,569,000 +$5,638,346 +71% 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2025 2024 FY
2022 $7,930,654 -$1,806,621 -19% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $9,737,275 -$859,720 -8.1% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $10,596,995 +$10,500,495 +10881% 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
2019 $96,500 -$8,810,674 -99% 01 Jan 2019 31 Dec 2019 10-K/A 16 Apr 2021 2020 FY
2018 $8,907,174 +$8,907,174 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
2017 $0 $0 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
2016 $0 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2017 2016 FY
2014 $280,590 -$66,665,046 -100% 01 May 2014 30 Apr 2015 10-K 16 Mar 2017 2016 FY
2013 $66,945,636 +$62,972,710 +1585% 01 May 2013 30 Apr 2014 10-K 16 Mar 2017 2016 FY
2012 $3,972,926 -$5,494,514 -58% 01 May 2012 30 Apr 2013 10-KT 14 Mar 2016 2015 FY
2011 $9,467,440 +$281,121 +3.1% 01 May 2011 30 Apr 2012 10-K 26 Jun 2013 2013 FY
2010 $9,186,319 01 May 2010 30 Apr 2011 10-K 25 Jul 2012 2012 FY

TENAX THERAPEUTICS, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $23,563,000 +$15,640,000 +197% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q1 2024 $7,923,000 -$6,091,793 -43% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q1 2023 $14,014,793 +$13,786,031 +6026% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q1 2022 $228,762 -$315,889 -58% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q1 2021 $544,651 -$1,585,394 -74% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q1 2020 $2,130,045 +$2,033,545 +2107% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q1 2019 $96,500 +$96,500 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q1 2018 $0 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q1 2016 $0 +$46,956 01 Jan 2016 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q2 2015 $51,785 -$248,222 -126% 01 May 2015 31 Jul 2015 10-Q 09 Sep 2015 2016 Q1
Q1 2015 $46,956 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q2 2014 $196,437 -$4,689,374 -96% 01 May 2014 31 Jul 2014 10-Q 09 Sep 2015 2016 Q1
Q2 2013 $4,885,811 +$2,427,547 +99% 01 May 2013 31 Jul 2013 10-Q 15 Sep 2014 2015 Q1
Q2 2012 $2,458,264 -$2,728,428 -53% 01 May 2012 31 Jul 2012 10-Q 17 Sep 2013 2014 Q1
Q2 2011 $5,186,692 +$315,197 +6.5% 01 May 2011 31 Jul 2011 10-Q 19 Sep 2012 2013 Q1
Q2 2010 $4,871,495 01 May 2010 31 Jul 2010 10-Q 19 Sep 2011 2012 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.